-
公开(公告)号：US09358213B2
公开(公告)日：2016-06-07
申请号：US12595838
申请日：2008-04-19
CPC分类号： A61K9/2886 , A61K9/2027 , A61K9/2059 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4891 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5078 , A61K31/381 , A61K47/585
摘要： The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.
摘要翻译： 本发明涉及度洛西汀或其药学上可接受的盐的药物组合物及其制备方法。
-
公开(公告)号：US20100209498A1
公开(公告)日：2010-08-19
申请号：US12595838
申请日：2008-04-19
IPC分类号： A61K9/48 , A61K31/381 , C07D333/20 , A61K9/14 , A61K9/28 , A61K9/40 , A61K9/58 , A61K9/62 , A61P25/24 , A61P29/00 , C08J5/20
CPC分类号： A61K9/2886 , A61K9/2027 , A61K9/2059 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4891 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5078 , A61K31/381 , A61K47/585
摘要： The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.
摘要翻译： 本发明涉及度洛西汀或其药学上可接受的盐的药物组合物及其制备方法。
-
3.发明申请Stabilized pharmaceutical compositions of dabigatran and process for preparation thereof 审中-公开稳定的达比加群的药物组合物及其制备方法公开(公告)号：US20150157618A1
公开(公告)日：2015-06-11
申请号：US14544126
申请日：2014-11-26
申请人： Chandrashekhar Kandi , Nagaprasad Vishnubhotla , Sreekanth Manikonda , Anil Kumar Reddy , Sivakumaran Meenakshisunderam , Arjuna Rao Panchada
发明人： Chandrashekhar Kandi , Nagaprasad Vishnubhotla , Sreekanth Manikonda , Anil Kumar Reddy , Sivakumaran Meenakshisunderam , Arjuna Rao Panchada
IPC分类号： A61K31/4439 , A61K9/48 , A61K9/20
CPC分类号： A61K31/4439 , A61K9/1652 , A61K9/1676 , A61K9/2013 , A61K9/2077 , A61K9/4808 , A61K9/4858
摘要： Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.
摘要翻译： 提供了包含凝血酶抑制剂作为活性剂的稳定化药物组合物，其制备方法及其使用方法。 本发明还涉及包含达比加群酯或其药学上可接受的盐，酯，水合物和溶剂合物的稳定的药物组合物，其制备方法及其使用方法。
-
4.发明申请Pharmaceutical compositions of anti-viral compounds and process for preparation thereof 审中-公开抗病毒化合物的药物组合物及其制备方法公开(公告)号：US20150141376A1
公开(公告)日：2015-05-21
申请号：US14544041
申请日：2014-11-18
申请人： Chandrashekhar Kandi , Nagaprasad Vishnubhotla , Asif Anwar , Krishna Kumar Chegonda , Sivakumaran Meenakshisunderam
发明人： Chandrashekhar Kandi , Nagaprasad Vishnubhotla , Asif Anwar , Krishna Kumar Chegonda , Sivakumaran Meenakshisunderam
IPC分类号： A61K9/20 , A61K31/506 , A61K31/675 , A61K31/536
CPC分类号： A61K9/2027 , A61K9/2018 , A61K31/506 , A61K31/513 , A61K31/536 , A61K31/675 , A61K2300/00
摘要： Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pharmaceutically acceptable excipients, process for preparation and method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected patient.
摘要翻译： 提供了抗病毒化合物的药物组合物，制备方法及其使用方法。 特别地，本发明涉及依法韦仑，恩曲他滨和替诺福韦地索普西富马酸与任选的一种或多种药学上可接受的赋形剂的化学稳定的药物组合物，其制备方法和用于治疗或预防感染HIV感染的症状或效果的方法 患者。
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
